iForumRx.org
STEP-ping Up the Game for Weight Management

STEP-ping Up the Game for Weight Management

July 16, 2021

More than two-thirds of adults in the United States are overweight or obese — thus, obesity is, by far, the most common preventable health-related problem seen in practice today. Obesity is associated with several comorbidities, and weight reduction leads to positive outcomes in many diseases. Studies have shown that a weight loss of 10% improves cardiovascular risk and outcomes. Unfortunately, current pharmacological options for weight loss do not consistently achieve a 10% weight loss.  Can semaglutide deliver?

Guest Panelists: Teney Mathew, PharmD, Jason Zupec, PharmD, BCACP, and Amy Heck Sheehan, PharmD, BCPS

Music by Good Talk

Raised From The Grave: A Second Life for Sotagliflozin?

Raised From The Grave: A Second Life for Sotagliflozin?

June 24, 2021

The prevalence of heart failure in patients with diabetes is four times higher than in the general population.  Likewise, chronic kidney disease (CKD) and diabetes are common morbidities. As new drug classes emerge in the management of diabetes and heart failure and CKD, it is important to thoroughly evaluate available literature and identify opportunities to reduce complications and costs. Sotagliflozin is a first-in-class dual SGLT-1 and 2 inhibitor approved in Europe.  Does it improve outcomes in patients with heart failure or CKD?

Guest Authors:  Maren Richards Brinton, PharmD and Jonathan C. Hughes, PharmD, BCPS, BCACP

Music by Good Talk

Tiny (n-of-1) Trials to Overcome Statin-Associated Muscle Pain

Tiny (n-of-1) Trials to Overcome Statin-Associated Muscle Pain

June 11, 2021

In blinded clinical trials the percentage of patients who experience muscle symptoms while taking a statin is typically in the 3-5% range.  In practice, the percentage of patients who report muscle symptoms is 10-25%.  This disparity between what has been observed in blinded trials and what patients experience when treated with a statin is due, in part, to the nocebo effect — a belief that a medication may cause harm.  How many lives could be saved if we routinely used tiny randomized, controlled, blinded trials to determine when statin therapy can be safely continued?

Guest Panelists: Elizabeth Hearn, PharmD; Stuart T Haines PharmD, BCPS, BCACP; and Kathryn (Katie) Kiser, PharmD, BCACP

Music by Good Talk

Top Ten Things Every Clinician Should Know About Infographics

Top Ten Things Every Clinician Should Know About Infographics

May 28, 2021

An infographic is an “informational graphic” that integrates design with data in order to visually communicate information in a clear, concise, and comprehensive manner. The use of these visual tactics can be powerful tools to enhance engagement, increase comprehension, and long-term retention of information.  Our guests explain how to create a successful infographic that can amplify the key educational messages to your targeted audience.  Be sure to download the Infographic about creating Infographics on the iForumRx website!

Guest Authors:  Ashley Barlow, PharmD and Brooke Barlow, PharmD

Music by Good Talk

Mind Over Migraine: Can Mindfulness Improve Outcomes?

Mind Over Migraine: Can Mindfulness Improve Outcomes?

May 14, 2021

Nearly 12% of the population suffers from migraine headaches — which not only negatively impacts patients, but causes a major “headache” for the healthcare system, costing billions for treatment, evaluation, and lost productivity costs in the United States alone. Two-thirds of patients discontinue prophylactic or abortive migraine therapies due to ineffectiveness or adverse effects. Can mindfulness exercises help migraine sufferers find their “Zen”?

Guest Authors:  Denver Shipman, PharmD, BCPP and Elizabeth Cook, PharmD, AE-C, BCACP, CDCES

Guest Panelist: Rebecca Castner, PharmD, BCACP, AAHIVP

Music by Good Talk

Is Home Blood Pressure Monitoring a “Home Run” for Blood Pressure Management?

Is Home Blood Pressure Monitoring a “Home Run” for Blood Pressure Management?

April 29, 2021

Nearly 67 million people, which equates to 3 out of every 4 people, living with high blood pressure in the US remain uncontrolled, despite the clear and compelling benefits of achieving good control. Remote monitoring and self-management of BP may enable us to broadly achieve optimal BP control in most patients. Increased use of telehealth technology improves access to care, but the effects on the cost and quality of care, particularly in the context of hypertension management, have not been clearly established.

Guest Authors: Mary Taylor, PharmD and Megan Supple, PharmD, BCACP, CPP

Guest Panelist:  Joseph Saseen, PharmD, BCPS, BCACP, CLS

Music by Good Talk

Increasing the Patient-Clinician Connection: the “Presence 5 Practices”

Increasing the Patient-Clinician Connection: the “Presence 5 Practices”

April 16, 2021

Amidst scientific and technological advancements and an increasing focus on administrative tasks and metrics, meaningful connections with patients are falling by the wayside. Mindlessly using technology can be distracting and lower patient perceptions of their quality of care. How can the busy practitioner increase “presence” with patients while still meeting clinical and administrative demands?

Guest Authors: Emily Prohaska, PharmD, BCACP, BCGP and Nick Schulte, PharmD, BCPS

Music by Good Talk

FAST Take: Update on Febuxostat Cardiovascular Safety

FAST Take: Update on Febuxostat Cardiovascular Safety

April 2, 2021

We know gout is among the many comorbidities that increase the risk of cardiovascular disease (CVD). In 2018, the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial concluded that febuxostat was non-inferior to allopurinol. BUT, two of the secondary endpoints were very concerning. Febuxostat was inferior to allopurinol in terms of cardiovascular death and all-cause mortality. Many clinicians were left wondering whether febuxostat was cardiotoxic …. or conversely, perhaps allopurinol was cardioprotective. Will another cardiovascular outcome trial provide greater clarity to guide clinical practice?

Guest Authors: Sophia Dietrich, PharmD and Michael W. Nagy, PharmD, BCACP

Guest Panelist: Dawn Fuke, PharmD, BCPS

Music by Good Talk

Metformin During Pregnancy: Are the Results MiTy Enough to Change Practice?

Metformin During Pregnancy: Are the Results MiTy Enough to Change Practice?

March 19, 2021

The American Diabetes Association (ADA) currently recommends insulin as the preferred agent for the management of type 2 diabetes mellitus during pregnancy. However, metformin is routinely used as it has several advantages over insulin including the lower cost, less maternal weight gain, and less maternal hypoglycemia. The MiTy study explores the benefits and risks of a combination of metformin plus insulin. 

Guest Authors:  Hugh Quinn, PharmD and Mallory Telese, PharmD
Guest Panelists: Erin Raney, PharmD, BCPS, BC-ADM and Rebecca Stone, PharmD, BCPS, BCACP

Music by Good Talk

Can a Polypill ‘TIP’ the Scale to a One-Size-Fits All Approach?

Can a Polypill ‘TIP’ the Scale to a One-Size-Fits All Approach?

February 26, 2021

Creating an ideal therapeutic regimen is often like putting a puzzle together, with adherence being a critical piece of that puzzle. Studies, and clinical experience, show that patients are more likely to adhere to once-daily medication administration when compared to regimens that require more frequent dosing.  Given that pill burden and medication cost are an increasing problem, would our patients benefit from a simple, low-cost, one-size-fits-all approach to addressing cardiovascular risk?

Guests:  Ebony Isis Evans, PharmD, Katy Pincus, PharmD, BCPS, BCACP, and Sara Wettergreen, PharmD, BCACP

Music by Good Talk

Podbean App

Play this podcast on Podbean App